Project Details
Description
VX12-809-105: A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mut
| Status | Finished |
|---|---|
| Effective start/end date | 12/6/13 → 12/6/16 |
Funding
- Vertex Pharmaceuticals Incorporated
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.